Recombinant PTK7 (Cofetuzumab Biosimilar) antibody
Quick Overview for Recombinant PTK7 (Cofetuzumab Biosimilar) antibody (ABIN7581642)
Target
Antibody Type
Reactivity
Host
Clonality
Conjugate
Application
-
-
Expression System
- CHO Cells
-
Purpose
- Anti-PTK7 / CCK4 Reference Antibody (cofetuzumab)
-
Sequence
- QVQLVQSGPE VKKPGASVKV SCKASGYTFT DYAVHWVRQA PGKRLEWIGV ISTYNDYTYN NQDFKGRVTM TRDTSASTAY MELSRLRSED TAVYYCARGN SYFYALDYWG QGTSVTVSSA STKGPSVFPL APSSKSTSGG TAALGCLVKD YFPEPVTVSW NSGALTSGVH TFPAVLQSSG LYSLSSVVTV PSSSLGTQTY ICNVNHKPSN TKVDKKVEPK SCDKTHTCPP CPAPELLGGP SVFLFPPKPK DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV YTLPPSRDEL TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM HEALHNHYTQ KSLSLSPG,EIVLTQSPAT LSLSPGERAT LSCRASESVD SYGKSFMHWY QQKPGQAPRL LIYRASNLES GIPARFSGSG SGTDFTLTIS SLEPEDFAVY YCQQSNEDPW TFGGGTKLEI KRTVAAPSVF IFPPSDEQLK SGTASVVCLL NNFYPREAKV QWKVDNALQS GNSQESVTEQ DSKDSTYSLS STLTLSKADY EKHKVYACEV THQGLSSPVT KSFNRGEC
-
Characteristics
- Anti-PTK7 / CCK4 Reference Antibody (cofetuzumab) is expressed from CHO. The heavy chain type is huIgG1, and the light chain type is hukappa. It has a predicted MW of 145.5 kDa.
-
Purity
- >95 %
-
Isotype
- IgG1
-
-
-
-
Application Notes
- Optimal working dilution should be determined by the investigator.
-
Comment
-
Therapeutic Agents by Target and Mechanism: PTK7 regulators
-
Restrictions
- For Research Use only
-
-
-
Format
- Lyophilized
-
Concentration
- 1 mg/mL
-
Buffer
- 25 mM histidine, 8 % sucrose, 0.01 % Tween80 pH 6.2
-
Storage
- 4 °C,-80 °C
-
Storage Comment
- +4°C,-80°C
-
-
- PTK7 (Cofetuzumab Biosimilar)
-
Target Type
- Biosimilar
-
Molecular Weight
- 145.5 kDa
-
UniProt
- Q13308-1
Target
-